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Background
Osteosarcoma is the most common primary malignant
bone tumour in children and young adults. Survival has
improved from historic rates of <20% to current rates of
50%–75% with multimodality therapy. Despite advances
in the diagnosis and management of osteosarcoma, there
have been few recent studies describing the experiences of
tertiary referral centers. We aim to describe and discuss the
clinical features, management and outcomes of these
patients in a single institution.
Materials and methods
Retrospective study of 100 consecutive patients managed
for osteosarcoma at Instituto Nacional de Cancerologia
(Distrito Federal, México) between 1985 and 1995. Sur-
vival curves were generated using the Kaplan-Meier and
the log rank test.
Results
Median age at diagnosis was 21 (range, 13–70) years.
Gender distribution was: 59 male and 41 female patients
with a relation male-female 1.4–1. Pain was the most
common presenting symptom in fifty-five patients (55%).
Median tumor size was 15 cm. 55 patients (55%) had
osteosarcoma in the femur, 22 in tibia, in the humerus 9
and others 14. At the diagnosis, 33 patients had metastatic
disease, the highest rate was lung metastasis (79%) fol-
lowed of bone metastasis (12%) The surgical resection
was realized in 93 patients, with radical surgery in 62
patients and limb sparing 31 patients. All but twenty-four
patients received chemotherapy; of patients who were
administered chemotherapy, 33 patients received neoad-
juvant chemotherapy and 43 adjuvant chemotherapy. In
five patients received radiotherapy.
The median follow-up time for surviving patients was 44
months (range, 2–240) for the 10-year periods. Following
initial therapy, over fifteen percent of patients remained
relapse-free during the follow-up period. The median of
survival for the patients with stage I of the American Joint
Committee on Cancer (AJCC) was 103 months, II (72
months), III (92 months), IV (17 months) (P = 0.0019).
The median of survival for the patients without or with
metastasis was of 71 months vs 16 months (P = 0.001).
Conclusion
Patient outcomes can be optimized through a multidisci-
plinary approach in a tertiary referral centre. In the Insti-
tuto Nacional de Cancerologia survival and relapse rates
of patients managed for osteosarcoma compare unfavour-
ably with the published literature actually. A poor survival
in this period of study reflected the lack of effective treat-
ment as the chemotherapy. Our results in this period are
comparable to the results of it period pre chemotherapy.
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